NewTimeSpace News: CITIC SEC (06030.HK) plans to issue in total 794.06 million shares.
NewTimeSpace News, May 28, 2026, CAPITAL VC(02324.HK) released its Interim Report for the period ended September 30, 2026, Total Revenue stood at -HKD 1.11 million, decreased by 300.93% YoY
NewTimeSpace News, May 28, 2026, MEDIA CHINESE(00685.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at USD 151.91 million, increased by 0.08% YoY
NewTimeSpace News: May 28, 2026, DYNAM JAPAN(06889.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at JPY 123.19 billion, decreased by 2.29% YoY
NewTimeSpace News: May 28, 2026, JOHNSON ELEC H(00179.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at USD 3.65 billion, increased by 0.08% YoY
NewTimeSpace News: May 28, 2026, MELBOURNE ENT(00158.HK) released its Interim Report for the period ended September 30, 2026, Total Revenue stood at HKD 81.52 million, decreased by 0.52% YoY
May 28, 2026, ONE MEDIA GROUP(00426.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 32.77 million, increased by 1.42% YoY
NewTimeSpace News: CIPRUN TECH (01020.HK) plans to issue in total 400 million shares.
May 28, 2026, LI AUTO-W(02015.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at CNY 22.98 billion, decreased by 11.35% YoY
May 28, 2026, AUTOHOME-S(02518.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at CNY 1.05 billion, decreased by 27.88% YoY
May 28, 2026, XPENG-W(09868.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at CNY 13.03 billion, decreased by 17.56% YoY
May 28, 2026, WB-SW(09898.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at USD 421.33 million, increased by 6.17% YoY
NewTimeSpace News: Innocare Pharma Limited (09969.HK) announced that the New Drug Application (NDA) for orelabrutinib, a Bruton’s Tyrosine Kinase (BTK) inhibitor, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration (NMPA) for the treatment of immune thrombocytopenia (ITP). Currently, no BTK inhibitor has been approved for ITP treatment in China, and orelabrutinib is expected to become a preferred therapy in this field.
NewTimeSpace News: Ocumension Therapeutics(01477.HK) announced that the first patient has been enrolled in the Phase III clinical trial of OT-802 (Pilocarpine Hydrochloride Eye Drops) conducted in China. Indicated for the treatment of presbyopia, the product adopts the same dual-chamber liquid formulation technology as OT-101. Preclinical studies have proven its rapid onset of action and high safety profile.
NewTimeSpace News: On May 28, Singapore-listed company Ascent Bridge announced it has signed a framework cooperation agreement with Huanuosen (Shenzhen) Gene Industry. The two parties plan to set up a joint venture in Singapore, introduce Gendicine, the world's first approved cancer gene therapy drug, and build gene diagnosis and treatment centers.
NewTimeSpace News: On May 28, Transurban Queensland priced a total of AUD 720 million senior secured notes, comprising AUD 400 million notes with a 7.25-year tenor and AUD 320 million notes with a 10-year tenor.
